Phase 3
Completed N=225
MK0476 Study in Adult Patients With Acute Asthma (0476-322)
Source: ClinicalTrials.gov NCT00229970 ↗Enrolled (actual)
225
Serious AEs
—
Results posted
Jul 2009
Primary outcomePrimary: The Time-weighted Average of Change in Forced Expiratory Volume in One Second (FEV1) — 0.09; 0.17; 0.01 Liter — p=0.022
Summary
This study evaluates the efficacy and safety of MK0476 intravenous administration in adult patients with acute asthma.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY The Time-weighted Average of Change in Forced Expiratory Volume in One Second (FEV1) |
0.09; 0.17; 0.01 | 0.022 sig |
Eligibility Criteria
Inclusion Criteria
- Adult Patients With Acute Asthma Attacks
Exclusion Criteria
- Patient Has Any Known Or Suspected, Acute Or Chronic Cause For Their Pulmonary Symptoms Other Than Asthma (E.G., Copd, Chronic Heart Failure, Etc.)
- Patient Has A Smoking History (20 Cigarettes Per Day) Of More Than 15 Years
- Patient Has A Disease Of The Cardiovascular, Hepatic, Renal, Hematologic Systems, Or Other Severe Disease
Data sourced from ClinicalTrials.gov (NCT00229970). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.